This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Browse

Lutein

Xanthophyll carotenoid concentrated in retinal macula + cerebral cortex.

Aliases (11)
LUTEIN · all-(E)-lutein · (3R,3'R,6'R)-β · ε-carotene-3 · 3'-diol · FloraGLO · Xangold (ester form) · marigold-derived lutein · 3R · 3'R · 6'R-lutein
TYPICAL DOSE
10 mg lutein + 2 mg zeaxanthin once daily with …
ROUTE
CYCLE
STORAGE

Overview

What is Lutein?

Xanthophyll carotenoid concentrated in retinal macula + cerebral cortex. AREDS2-protocol dose is 10 mg lutein + 2 mg zeaxanthin daily with a fat-containing meal — three months to plateau on MPOD, six months to plateau on visual performance gains. Strong evidence for retinal protection in older AMD-risk populations (AREDS2 + 10-yr follow-up); reasonable young-adult evidence for contrast sensitivity, glare recovery, photostress recovery, and visual fatigue in screen-heavy users (Stringham 2017, Lopresti 2025). Safety is excellent — only side effect is reversible carotenodermia at >20 mg/day chronic intake. For Dylan: OPTIONAL-ADD. Computer work + MMA visual demands make a case, but dietary lutein (2 cups leafy greens + 2 egg yolks daily) saturates serum response — supplement only if diet falters during cutting phases or training camps where greens consistency drops. Skip if smoking history is the only flag (lutein is safe in smokers — unlike beta-carotene). FloraGLO free-form lutein is the gold-standard ingredient brand; marigold-flower-derived. ~$8-12/month.

Research Indications

Most Effective

Macula lutea

Lutein + zeaxanthin + meso-zeaxanthin accumulate in Henle's fiber layer surrounding the foveola at ~1,000× the concentration of any other…

Effective

Cerebral cortex

Frontal and occipital cortex specifically — emerging evidence ties cortical lutein concentration to cognitive performance independent of …

Investigational

Skin

Modest accumulation; contributes to photoprotection at high intakes.

Investigational

Adipose

Storage depot.

Peptide Interactions

zeaxanthin (mandatory pairing):
Synergistic

AREDS2 protocol = 10 mg L + 2 mg Z (5:1 ratio, the natural ratio in retinal macular pigment). Lutein dominates parafoveal macula; zeaxanthin dominates fovea.…

meso-zeaxanthin:
Synergistic

Some formulations add 0.5-2 mg meso-zeaxanthin. Meso-zeaxanthin is endogenously formed in the retina from lutein via RPE65 isomerization, but supplemental me…

omega-3 (especially DHA):
Synergistic

DHA is the major lipid in photoreceptor outer-segment membranes. Lutein partitions into these same membranes. AREDS2 sub-analyses showed an interaction (L+Z …

vitamin E (α-tocopherol):
Synergistic

Regenerates oxidized carotenoid radicals and shares lipoprotein transport. Mild kinetic synergy.

vitamin C:
Synergistic

Recycles oxidized vitamin E, indirectly supporting the carotenoid recycling pathway. Already V4-locked.

zinc:
Synergistic

Original AREDS formula component. RPE concentrates zinc and uses it as antioxidant cofactor. Modest direct synergy with L+Z protection of retinal tissue.

astaxanthin:
Synergistic

Different carotenoid class (ketocarotenoid) — partitions into both leaflets of the bilayer where lutein has a surface preference. Some evidence (Senju 2023) …

dietary fat (5+ g per dose):
Synergistic

Tripled to quadrupled absorption. Not a "stack" per se but co-ingestion with fat is non-negotiable for full bioavailability.

beta-carotene at high dose (>10-15 mg):
Avoid

Competes at intestinal SR-BI/CD36 carotenoid uptake transporters. High-dose beta-carotene can reduce serum lutein by 30-40%. Plus the former-smoker lung canc…

Cholestyramine, orlistat, plant sterol esters:
Avoid

Bile-acid sequestrants and fat-blockers reduce carotenoid absorption.

Fat-free or very-low-fat meal:
Avoid

Functional zero absorption.

What to Expect

  • Week 1
    Tolerability and dose-response.
  • Week 2-4
    Early effect window.
  • Week 4-8
    Peak benefit assessment.
  • Week 8+
    Cycle decision point.

Side Effects & Safety 3

Side Effects

  1. 1Carotenodermia (yellowing of palms, soles, and to a lesser extent face) at high chronic doses (>20 mg/day for several months). Harmless, reversible on dose reduction or discontinuation. Distinct from jaundice — sclerae are spared, not pathologic. More common in lighter-skinned individuals where the contrast is visible.
  2. 2Mild GI upset if taken on empty stomach (rare, mitigated by fat co-ingestion).
  3. 3Aesthetic carotenoid-driven skin tint that may be desirable or undesirable depending on user preference — research-grade users sometimes report a subtle "warmer skin tone" within 8-12 weeks.

When to Stop

  • Crystalline lutein maculopathy — exceptional cases at extremely high chronic intakes (>20 mg/day for multi-year duration combined with high-fat diet). Reversible on discontinuation. Functionally not a concern at AREDS2 doses.
  • No documented serious adverse events at supplementation doses in the 4,203-participant AREDS2 trial over 5 years and 10-year follow-up. Long-term safety is among the best-characterized in the entire supplement universe.
  • CARET trial (1996): 30 mg beta-carotene + 25,000 IU retinyl palmitate in smokers/asbestos workers — STOPPED EARLY due to 28% increase in lung cancer incidence.
  • ATBC trial (1994): 20 mg beta-carotene in male smokers — 18% increase in lung cancer.
  • AREDS2 10-year follow-up (2022): Beta-carotene OR 1.82 for lung cancer in former smokers; lutein/zeaxanthin OR 1.15 (ns) — no excess risk.

References

Chew EY et al. 2013 — AREDS2 trial primary report (JAMA, PMID 23644932)

pubmed.ncbi.nlm.nih.gov · 2013

pivotal 5-year RCT, n=4,203, lutein/zeaxanthin replaced beta-carotene in revised AREDS formulation.

View Study

Chew EY et al. 2022 — AREDS2 Report 28, 10-year follow-up (JAMA Ophthalmology, PMID 35653117)

pubmed.ncbi.nlm.nih.gov · 2022

definitive long-term safety + efficacy data; beta-carotene lung cancer signal in former smokers; lutein/zeaxanthin reassuring.

View Study

Stringham JM et al. 2017 — Macular carotenoid supplementation in high screen-time users (Foods, PMID 28661438)

pubmed.ncbi.nlm.nih.gov · 2017

6-month RCT, 48 young adults ≥6 hr/day screens; improved MPOD, visual performance, eye strain, headache, sleep quality.

View Study

Renzi-Hammond LM et al. 2017 — L+Z in young healthy adults cognitive function (Nutrients, PMID 29135938)

pubmed.ncbi.nlm.nih.gov · 2017

12-month RCT, n=51, increased spatial memory at AREDS2 dose.

View Study

Hammond BR et al. 2017 — L/Z in older adults cognitive function (Frontiers Aging Neurosci, PMID 28824416)

pubmed.ncbi.nlm.nih.gov · 2017

1-year RCT, improved complex attention + cognitive flexibility.

View Study
Was this helpful?
Your feedback shapes what we research deeper.

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load
Loading…
Continue: Extended research →
Our verdict, decision matrix, deep dives, controversies, sources